Intravenous Immunoglobulin Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025- Growing geriatric population, rising prevalence of immunodeficiency diseases, increasing adoption of IVIG treatments and rising use of off-label indications are the key drivers of the Global Intravenous Immunoglobulin Market.
Global Intravenous Immunoglobulin Market is valued at USD 9804.8 Million in 2018 and expected to reach USD 16587.0 Million by 2025 with the CAGR of 7.80% over the forecast period.
Scope of Global Intravenous Immunoglobulin Market Report–
Intravenous Immunoglobulin (IVIg), a compound comprising of immune proteins (globulins) is administered into the bloodstream to treat patients with inefficient or damaged immune systems. IVIg provides the required antibodies to the human body to fight out the immune deficiency, and the ensuing infectious attacks. Immunoglobulin also referred as antibodies, are the glycoprotein molecules manufactured by the plasma or white blood cells. Immunoglobulin’s form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction. In certain individual, immunoglobulins have to be administered for the treatment and management of disease such as primary immunodeficiency (PI). Intravenous immunoglobulins are the most popular form of immunoglobulin due to the no requirement for self-administration and the easy administration in hospital and clinic settings. Different classes of immunoglobulin such as IgA, IgG, and IgM are used for the treatment of various neurological and immunological diseases.
Get Sample Copy of This Premium Report @ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=4968&RequestType=Sample
Global Intravenous Immunoglobulin market report is segmented on the basis of type, application, end-users and region & country level. Based on type, global intravenous immunoglobulin market is classified into IgG, IgA, IgM, IgE and IgD. Based on application global intravenous immunoglobulin market is classified into hypogammaglobulinemia, immunodeficiency diseases, congenital AIDS, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, multifocal motor neuropathy, ITP, Guillain-Barre syndrome, Kawasaki Diseases and others. Based on end-user, global intravenous immunoglobulin market is classified into hospitals, clinics, homecare and others.
The regions covered in this intravenous immunoglobulin market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of intravenous immunoglobulin is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Key Players for Global Intravenous Immunoglobulin Market Report-
Global intravenous immunoglobulin market report covers prominent players like Omrix Biopharmaceuticals Ltd., Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co. Ltd., Behring GmbH, Option Care Enterprises, Inc., BioScrip, Inc, ADMA Biologics, Inc., CSL Ltd., Baxter International Inc., Kedrion Biopharma Inc., Grifols S.A, LFB group, Octapharma AG, ADMA Biologics, Inc., China Biologics Products, Inc., Biotest AG, Takeda Pharmaceuticals and among others.
FDA Approved ASCENIV, a Novel Intravenous Immune Globulin.
On April 1st, 2019, ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced that the U.S. Food and Drug Administration (FDA) approved ASCENIV, Immune Globulin Intravenous, Human – slra 10% Liquid, formerly referred to as RI-002. ASCENIV is an Intravenous Immune Globulin (IVIG) drug product for the treatment of Primary Humoral Immunodeficiency Disease (PIDD or PI) in adults and adolescents (12 to 17 years of age). The Company anticipates having the product available for commercial launch during the second half of 2019.
Global Intravenous Immunoglobulin Market Dynamics–
Rising elderly population, increasing occurrence of immunodeficiency disorders, growing implementation of IVIG procedures and increasing usage of off-label indications are some of the major factors driving the market growth. Increasing number of patients with immunodeficiency disease is the primary reason for the expansion of IVIG procedures. According to the World Health Organization (WHO), there are approximately 50 diverse Primary Immune Deficiency (PID) such as X-lined hypo-gamma-globulinemia, specific antibody deficiency and others. Furthermore, according to the U.S. National Library of Medicine and National Institute of Health, around 6 million patients are suffering from Primary Immune Deficiency (PID) globally. Rising occurrences of these immune diseases is expected to foster the demand for intravenous immunoglobulin treatments during the forecast period. However, stringent government regulations regarding the use of intravenous immunoglobulin products and high risk of side effects associated with them are expected to hinder the growth of the market. Moreover, high adoption of intravenous immunoglobulins for the treatment of various diseases is expected to create lucrative opportunities in the near future.
Request for Methodology @ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=4968&RequestType=Methodology
Global Intravenous Immunoglobulin Market Regional Analysis–
North America is expected to dominate the global intravenous immunoglobulin market. Increasing healthcare expenditure, growing level of consciousness for the products involved in the treatment of immunodeficiency disorders, and rising inclination of clinicians towards immunodeficiency therapies are the key factors attributing towards the market growth. Additionally, growing occurrences of primary immunodeficiency (PID) is also expected to enhance the market growth in this region. According to American Autoimmune Related Disease Association Inc. (AARDA) 2012, approximately 50 million Americans were diagnosed to have autoimmune diseases and the number of people suffering this disease.
Asia Pacific is expected to show a significant growth at a considerable CAGR over forecast period owing to the increasing awareness and potential opportunities for adoption of immunoglobulin based therapies for the treatment of primary immune deficiencies coupled with growing geriatric population in this region.
Key Benefits for Global Intravenous Immunoglobulin Market Report–
Global Intravenous Immunoglobulin Market report covers in depth historical and forecast analysis.
Global Intravenous Immunoglobulin Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global Intravenous Immunoglobulin Market report helps to identify opportunities in market place.
Global Intravenous Immunoglobulin Market report covers extensive analysis of emerging trends and competitive landscape.
Buy this Report @ https://brandessenceresearch.biz/Buy/Create/4968/Buy/SingleUser
Global Intravenous Immunoglobulin Market Segmentation: –
Chronic Inflammatory Demyelinating Polyneuropathy
Multifocal Motor Neuropathy
By Regional & Country Analysis:
The Middle East and Africa
Rest of Middle East and Africa
Table of Content
1. Chapter – Report Methodology
1.1. Research Process
1.2. Primary Research
1.3. Secondary Research
1.4. Market Size Estimates
1.5. Data Triangulation
1.6. Forecast Model
1.7. USP’s of Report
1.8. Report Description
2. Chapter – Global Intravenous Immunoglobulin (IVIg) Market Overview: Qualitative Analysis
2.1. Market Introduction
2.2. Executive Summary
2.3. Global Intravenous Immunoglobulin (IVIg) Market Classification
2.4. Market Drivers
2.5. Market Restraints
2.6. Market Opportunity
2.7. Intravenous Immunoglobulin (IVIg) Market: Trends
2.8. Porter’s Five Forces Analysis
2.8.1. Bargaining Power of Suppliers
2.8.2. Bargaining Power of Consumers
2.8.3. Threat of New Entrants
2.8.4. Threat of Substitute Product and Services
2.8.5. Competitive Rivalry within the Industry
2.9. Market Attractiveness Analysis
2.9.1. Market Attractiveness Analysis by Segmentation
2.9.2. Market Attractiveness Analysis by Region
3. Chapter – Global Intravenous Immunoglobulin (IVIg) Market Overview: Quantitative Analysis
4. Chapter – Global Intravenous Immunoglobulin (IVIg) Market Analysis: By Type
5. Chapter – Global Intravenous Immunoglobulin (IVIg) Market Analysis: By Application
6. Chapter – Global Intravenous Immunoglobulin (IVIg) Market Analysis: By Manufacturer
7. Chapter –Intravenous Immunoglobulin (IVIg) Market: Regional Analysis
8. Chapter – Company Profiles
8.1. Bharat Serums and Vaccines Limited
8.1.3. Product portfolio
8.1.4. Intravenous Immunoglobulin (IVIg) Market Revenue (USD Million) and Market Share (%), 2014 – 2018
8.1.5. Intravenous Immunoglobulin (IVIg) Sales Market Share (%), 2014 – 2018
8.1.6. Business strategy
8.1.7. Recent developments
8.2. Biotest AG
8.3. China Biologic Products, Inc.
8.4. Guizhou Taibang Biological Products Co., Ltd
8.5. CSL Limited
8.6. Grifols, S.A.
8.7. Hualan Biological Engineering Inc.
8.8. Kedrion S.p.A.
8.9. LFB Group
8.10. Octapharma AG
8.11. Shanghai RAAS Blood Products Co., Ltd.
8.12. Shire plc
8.13. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
About us: Brandessence Market Research and Consulting Pvt. ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at firstname.lastname@example.org